DBV Technologies (DBVT) Projected to Post Earnings on Thursday

DBV Technologies (NASDAQ:DBVT) is projected to post its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect DBV Technologies to post earnings of ($0.1935) per share and revenue of $1.0570 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 6:00 AM ET.

DBV Technologies Stock Down 0.2%

Shares of DBVT stock opened at $22.23 on Thursday. DBV Technologies has a twelve month low of $3.82 and a twelve month high of $26.18. The stock’s fifty day simple moving average is $20.66 and its 200 day simple moving average is $15.53. The firm has a market capitalization of $1.22 billion, a P/E ratio of -4.30 and a beta of -0.98.

Insiders Place Their Bets

In other news, major shareholder Bpifrance Epic sold 1,292,103 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $4.19, for a total value of $5,413,911.57. Following the transaction, the insider directly owned 7,303,369 shares of the company’s stock, valued at $30,601,116.11. The trade was a 15.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 3,369,627 shares of company stock worth $15,489,908. Company insiders own 1.44% of the company’s stock.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors have recently added to or reduced their stakes in the business. Artisan Partners Limited Partnership grew its holdings in DBV Technologies by 6,273.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after purchasing an additional 3,257,135 shares during the period. Vivo Capital LLC boosted its position in shares of DBV Technologies by 133.4% during the 4th quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock worth $47,189,000 after purchasing an additional 1,407,120 shares in the last quarter. Siren L.L.C. bought a new position in shares of DBV Technologies during the 4th quarter worth about $35,606,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. Finally, MPM Bioimpact LLC bought a new stake in DBV Technologies in the 2nd quarter valued at about $9,649,000. 71.74% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Citizens Jmp boosted their price objective on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 target price on DBV Technologies in a research report on Thursday, December 18th. Finally, Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, DBV Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $38.25.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.